ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...
TKT Stockholders Approve Acquisition by Shire CAMBRIDGE, Mass., July 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that TKT stockholders approved...
TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction CAMBRIDGE, Mass., July 14 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc...
TKT Issues Open Letter to Stockholders Board of Directors Urges TKT Stockholders to Vote 'FOR' Shire Transaction CAMBRIDGE, Mass., July 12 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc...
TKT to Hold Special Meeting of Stockholders on July 27, 2005 CAMBRIDGE, Mass., June 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced its plans to hold a...
TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial Primary Endpoint Achieves Statistical Significance CAMBRIDGE, Mass., June 20 /PRNewswire-FirstCall/ -- Transkaryotic...
TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- Transkaryotic...
TKT Announces First Quarter 2005 Results CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced its consolidated financial results for...
TKT Assessing Impact of Fire at Manufacturing Facility CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) announced that a fire occurred yesterday...
TKT to Report First Quarter 2005 Financial Results on May 5, 2005 CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) will announce its first quarter...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.